Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share ...

本文来自：华尔街见闻，作者：张雅琦，原文标题：《近两年来最大生物技术并购！强生百亿收购Intra-Cellular，后者盘前飙升近38%》 强生收购Intra-Cellular，将目光瞄准中枢神经系统疾病市场。 1月13日，强生公司以146亿美元收购Intra-Cellular Therapies，以增强其在神经 ...

Johnson & Johnson will acquire Intra-Cellular for $132 per share in cash, a 39 percent premium over Intra-Cellular's Friday closing price of $94.87. Following the announcement, shares of both ...

8, 2024. (AP Photo/Ted Shaffrey, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Johnson & Johnson will spend more than $14 billion to delve further into the treatment of ...

Johnson & Johnson will acquire Intra-Cellular Therapies for $132 per share in a deal that values the company at $14.6 billion. The acquisition includes FDA-approved CAPLYTA for schizophrenia and ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Johnson & Johnson JNJ4.13%increase; green up pointing triangle agreed to acquire mental-illness drug developer Intra-Cellular Therapies ITCI-0.11%decrease; red down pointing triangle for about $15 ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

Johnson & Johnson is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, people familiar with the matter said. A ...